InsidersTradesSigma
Follow the Aegerion Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 29 January 2016 (Levée d'options). Among the most active insiders: SMITH SANDFORD D. The full history is free.
Analysts rate Aegerion Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases. It is listed on NASDAQ under the ticker AEGR.